The Effect of Topical Bevacizumab on Corneal Neovascularization

Sang Woo Kim; Byung Jin Ha; Eung Kweon Kim; Hungwon Tchah; Tae im Kim

doi:10.1016/j.ophtha.2008.02.013

The Effect of Topical Bevacizumab on Corneal Neovascularization

Sang Woo Kim, Byung Jin Ha, Eung Kweon Kim, Hungwon Tchah, Tae im Kim

Department of Ophthalmology

Research output: Contribution to journal › Article › peer-review

185 Citations (Scopus)

Abstract

Purpose: To examine the effect of topical bevacizumab on corneal neovascularization (NV) over a period of 3 months. Design: Prospective, nonrandomized, masked observational case series. Participants: Ten eyes of 7 patients with corneal NV. Methods: Patients received topical bevacizumab (1.25%) twice daily. Ophthalmic evaluations included visual acuity, slit-lamp examination, and tonometry. Main Outcome Measures: Corneal NV and changes in ophthalmic evaluations. Results: Decreased corneal NV was noted in 7 of 10 eyes, usually within 1 month of treatment. Epitheliopathy (epithelial defect, epithelial erosion) was observed in 6 of 10 eyes, 1 resulting in corneal thinning. Adverse effects generally appeared during the second month of treatment. Conclusions: Topical application of bevacizumab was effective in reducing corneal NV within the first month. However, by the second month there was an increased risk of adverse effects.

Original language	English
Pages (from-to)	e33-e38
Journal	Ophthalmology
Volume	115
Issue number	6
DOIs	https://doi.org/10.1016/j.ophtha.2008.02.013
Publication status	Published - 2008 Jun

Bibliographical note

Funding Information:
This study was supported by Korean Research Foundation grant 2006-KRF-531-E00121.

All Science Journal Classification (ASJC) codes

Ophthalmology

Access to Document

10.1016/j.ophtha.2008.02.013

Cite this

@article{c80dcf406baa459395435cdc2e9d7453,

title = "The Effect of Topical Bevacizumab on Corneal Neovascularization",

abstract = "Purpose: To examine the effect of topical bevacizumab on corneal neovascularization (NV) over a period of 3 months. Design: Prospective, nonrandomized, masked observational case series. Participants: Ten eyes of 7 patients with corneal NV. Methods: Patients received topical bevacizumab (1.25%) twice daily. Ophthalmic evaluations included visual acuity, slit-lamp examination, and tonometry. Main Outcome Measures: Corneal NV and changes in ophthalmic evaluations. Results: Decreased corneal NV was noted in 7 of 10 eyes, usually within 1 month of treatment. Epitheliopathy (epithelial defect, epithelial erosion) was observed in 6 of 10 eyes, 1 resulting in corneal thinning. Adverse effects generally appeared during the second month of treatment. Conclusions: Topical application of bevacizumab was effective in reducing corneal NV within the first month. However, by the second month there was an increased risk of adverse effects.",

author = "Kim, {Sang Woo} and Ha, {Byung Jin} and Kim, {Eung Kweon} and Hungwon Tchah and Kim, {Tae im}",

note = "Funding Information: This study was supported by Korean Research Foundation grant 2006-KRF-531-E00121. ",

year = "2008",

month = jun,

doi = "10.1016/j.ophtha.2008.02.013",

language = "English",

volume = "115",

pages = "e33--e38",

journal = "Ophthalmology",

issn = "0161-6420",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - The Effect of Topical Bevacizumab on Corneal Neovascularization

AU - Kim, Sang Woo

AU - Ha, Byung Jin

AU - Kim, Eung Kweon

AU - Tchah, Hungwon

AU - Kim, Tae im

N1 - Funding Information: This study was supported by Korean Research Foundation grant 2006-KRF-531-E00121.

PY - 2008/6

Y1 - 2008/6

N2 - Purpose: To examine the effect of topical bevacizumab on corneal neovascularization (NV) over a period of 3 months. Design: Prospective, nonrandomized, masked observational case series. Participants: Ten eyes of 7 patients with corneal NV. Methods: Patients received topical bevacizumab (1.25%) twice daily. Ophthalmic evaluations included visual acuity, slit-lamp examination, and tonometry. Main Outcome Measures: Corneal NV and changes in ophthalmic evaluations. Results: Decreased corneal NV was noted in 7 of 10 eyes, usually within 1 month of treatment. Epitheliopathy (epithelial defect, epithelial erosion) was observed in 6 of 10 eyes, 1 resulting in corneal thinning. Adverse effects generally appeared during the second month of treatment. Conclusions: Topical application of bevacizumab was effective in reducing corneal NV within the first month. However, by the second month there was an increased risk of adverse effects.

AB - Purpose: To examine the effect of topical bevacizumab on corneal neovascularization (NV) over a period of 3 months. Design: Prospective, nonrandomized, masked observational case series. Participants: Ten eyes of 7 patients with corneal NV. Methods: Patients received topical bevacizumab (1.25%) twice daily. Ophthalmic evaluations included visual acuity, slit-lamp examination, and tonometry. Main Outcome Measures: Corneal NV and changes in ophthalmic evaluations. Results: Decreased corneal NV was noted in 7 of 10 eyes, usually within 1 month of treatment. Epitheliopathy (epithelial defect, epithelial erosion) was observed in 6 of 10 eyes, 1 resulting in corneal thinning. Adverse effects generally appeared during the second month of treatment. Conclusions: Topical application of bevacizumab was effective in reducing corneal NV within the first month. However, by the second month there was an increased risk of adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=44449119809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44449119809&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2008.02.013

DO - 10.1016/j.ophtha.2008.02.013

M3 - Article

C2 - 18439681

AN - SCOPUS:44449119809

SN - 0161-6420

VL - 115

SP - e33-e38

JO - Ophthalmology

JF - Ophthalmology

IS - 6

ER -

The Effect of Topical Bevacizumab on Corneal Neovascularization

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this